PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decision.

The New Zealand medical journal

Volumn 120, Issue 1259, 2007, Pages

  Isaacs, Richard J ^a   Frampton, Christopher M ^a   Kuper Hommel, Marion J J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DRUG INDUSTRY; ECONOMICS; FEMALE; HUMAN; NEW ZEALAND; NOTE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG INDUSTRY; FEMALE; HUMANS; NEW ZEALAND;

EID: 34548412758     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Note

References (0)